Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy.

At week 13, the proportion of patients with a 50% or greater reduction from baseline in NRS pain score (responders) was 26% for the placebo group and ranged from 32% to 37% for the desvenlafaxine dose groups ( Figure 3 ); differences from placebo did not reach statistical significance for any desvenlafaxine dose group.

also in 111,027 other papers